Real-world first-line treatment patterns and outcomes in recurrent/advanced endometrial cancer patients in Europe.

ABSTRACT: Background: The treatment patterns and clinical outcomes in recurrent/advanced endometrial cancer in Europe are not well known.Materials & methods: Endometrial Cancer Health Outcomes-Europe-First-Line is a multicenter, retrospective chart review study conducted in the UK, Germany, Italy, France and Spain. Patients diagnosed with recurrent/advanced endometrial cancer who initiated first-line systemic therapy between 1 July 2016 and 31 March 2020 were eligible.Results: Among 242 patients, median age was 69 years and 82.2% had stage IIIB-IV disease. In first-line, most patients received platinum-based chemotherapy (78.9%); others received endocrine therapy (6.2%), taxane monotherapy (5.8%) and nonplatinum or taxane-based chemotherapy (4.1%). Median real-world progression-

SUBMITTER: Zhang J 

PROVIDER: S-EPMC11534108 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature